[7] Packer M.(2020). SGLT2 Inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: A paradigm shift in understanding their mechanism of action, Diabetes Care, 43(3), 508–511. https://doi.org/10.2337/dci19-0074 [8] Packer ...
glomerular hypertension and hyperfiltration. The present review summarizes the current evidence from human trials on the effects of SGLT-2 inhibitors on nephroprotection and discusses their position in everyday clinical practice. Access options Subscribe to this journal...
[6].《钠-葡萄糖共转运蛋白2抑制剂联合二甲双胍治疗2型糖尿病专家共识》专家组. 钠-葡萄糖共转运蛋白2抑制剂联合二甲双胍治疗2型糖尿病专家共识[J]. 国际内分泌代谢杂志,2023,43(5):437-448. [7].Zannad F,Ferreira JP,Pocock SJ,et al. SGLT2 inhibitors in patients with heart failure with reduced...
Woo, Y.-C., Yuen, M.-F., Seto, W.-K., & Lam, K. S.-L. (2024). Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real-world study. Diabetes, Obesity and...
[17]. Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, Dimitriou T, Elisaf M. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opin Drug Metab Toxicol. 2018 Nov;14(11):1113-1121. doi: 10.1080/17425255.2018.1541348. Epub 2018 Oct 31. PMID: 30360662. ...
Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors.Diabetologia. 2018;61(10):2079-2086. doi:10.1007/s00125-018-4654-7 Benedict SL, Mahoney OM, McKee TS, Bergman PJ. Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus.Can J Vet Res. 2022;86(1):52-58...
[6].ESC-HFA 2024:Navigating the realms of SGLT2 inhibitors bridging clinical studies enthusiasm with practical realities.
该项研究结果表明SGLT2抑制剂可能在狼疮性肾炎中发挥积极地保护作用,为探索SGLT2抑制剂在非免疫抑制疗法中改善LN肾损伤提供了更多的线索。 主要发现 近日,Annals of The Rheumatic Diseases期刊在线发表了来自郑州大学第一附属医院肾脏病医院齐媛媛博士团队的题为“SGLT2 Inhibitors Alleviated Podocyte Damage in Lupus Ne...
知识来源 [1] SGLT2 Inhibitors Safe for HF in Congenital Heart Disease[EB/OL].(2024-04-05)[2024-04-09].https://www.medscape.com/viewarticle/sglt2-inhibitors-safe-hf-congenital-heart-disease-2024a10006ih
Sodium–glucose cotransporter 2 (SGLT2) inhibitors were initially developed for their glucose-lowering effects and have shown a modest glycaemic benefit in people with type 2 diabetes mellitus (T2DM). In the past decade, a series of large, robust clinica